You are about to download this document, please enter your contact details below to start downloading.
An Open-label, Two-period Study Designed to Evaluate and Compare the Mass Balance Recovery and Metabolite Profile of 14C-Deutetrabenazine and 14C-Tetrabenazine in Healthy Male Subjects
Deutetrabenazine (Austedo, Teva) is approved for the treatment of chorea associated
with Huntington’s disease (HD) and tardive dyskinesia (TD). Deutetrabenazine is the
first deuterated product approved by the FDA and only the second product approved
in HD and TD.
Deutetrabenazine is a novel VMAT2 inhibitor that is structurally related to
tetrabenazine, with two trideuteromethoxy groups at the 9- and 10-positions in